RemeGen Co., Ltd. — Capital/Financing Update 2021

Dec 22, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [112 x 39] intentionally omitted <==

RemeGen Co., Ltd.[*] 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 9995)

VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE FIRST H SHARE AWARD AND TRUST SCHEME

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the ‘‘Company’’) on a voluntary basis. Reference is made to the announcements of the Company dated February 3, 2021 and March 23, 2021 (the ‘‘Announcements’’), and the circular dated March 5, 2021 (the ‘‘Circular’’), in relation to the adoption of the First H Share Award and Trust Scheme. Capitalized terms used herein shall have the same meanings as those defined in the Announcements and Circular unless the context requires otherwise.

On December 22, 2021, the Trustee purchased a total number of 70,000 Shares (the ‘‘Share Purchase’’) on the market, at a consideration from approximately HK$76.90 to HK$80.00 per Share and a total consideration of approximately HK$5,500,000 in aggregate, pursuant to the First H Share Award and Trust Scheme as a long-term equity incentive for employees in the future.

As at the date of this announcement, no Award Shares have been granted to any Selected Participants to the First H Share Award and Trust Scheme. The Board of Directors or its Delegatee will have full discretion to determine the number of shares to be granted to Selected Participants under the First H Share Award and Trust Scheme together with vesting criteria and conditions as it deems appropriate.

– 1 –

The Company may make further announcements on the status of the First H Share Award and Trust Scheme, including the number and price of the Shares purchased, from time to time.

By order of the Board RemeGen Co., Ltd.* Mr. Wang Weidong

Chairman and executive director

Yantai, the People’s Republic of China December 22, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

• For identification purposes only

– 2 –